Difference between revisions of "Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3) (Q10740)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: named entity (P78): eculizumab (chemical - MeSH supplementary concept) (Q10955), #quickstatements; #temporary_batch_1592945455790)
(‎Created claim: named entity (P78): Adalimumab (chemical - MeSH descriptor) (Q10969), #quickstatements; #temporary_batch_1592945455790)
Property / named entity
 +
Property / named entity: Adalimumab (chemical - MeSH descriptor) / rank
 +
Normal rank

Revision as of 20:51, 23 June 2020

Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3
Language Label Description Also known as
English
Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)
Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3

    Statements

    0 references
    Q10356 (Deleted Item)
    0 references
    Q10356 (Deleted Item)
    0 references
    0 references
    0 references
    0 references
    0 references